ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1392

The Expression Of Proto-Oncogene Survivin Splicing Variant 2B In Synovial Tissues and Blood From Patients With Rheumatoid Arthritis

Sho Mokuda1,2, Tatsuhiko Miyazaki3, Junya Masumoto3, Masamoto Kanno4 and Kiyoshi Takasugi5, 1Department of Immunology, Graduate School of Biomedical Sciences, Hiroshima University, Hiroshima, Japan, 2Department of Internal Medicine, Center for Rheumatic Diseases, Dohgo Spa Hospital, Matsuyama, Japan, 3Department of Pathology, Division of Analyticalpathology, Ehime University Graduate School of Medicine, Toon, Japan, 4Department of Immunology, Graduate School of Biomedical Sciences, Hiroshima University, Hirosima, Japan, 5Center for Rheumatic Diseases, Dohgo Spa Hospital, Matsuyama, Japan

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Apoptosis, Fibroblasts, rheumatoid arthritis (RA) and synovitis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Rheumatoid Arthritis - Human Etiology and Pathogenesis

Session Type: Abstract Submissions (ACR)

Background/Purpose: It has been reported that serum survivin level was an independent risk factor for predicting joint destruction in early rheumatoid arthritis (RA). The proto-oncogene BIRC5 generates alternative splicing variants, including wild-type (WT) survivin, survivin 2B, survivin delta-Ex3, survivin 3B and survivin 2-alpha. We herein examined which variants of survivin were expressed in the synovial tissues and blood samples of patients with RA and osteoarthritis (OA).

Methods: We observed the expression of survivin splicing variants in synovial tissues by the real-time PCR and immunohistochemistry (IHC) analyses, and serum survivin 2B was measured with enzyme-linked immunosorbent assay (ELISA). Moreover, to determine the effects of survivin splicing variants in fibroblasts, cell viability and chemosensitivity of an anti-metabolite were evaluated by overexpression experiments in a fibroblast model with the MTS and LDH assays.

Results: We found that three types of splicing variant (WT survivin, survivin 2B and survivin delta-Ex3) were expressed in RA and OA synovial tissues by RT-PCR, and the WT survivin and survivin 2B mRNA expression levels in RA synovial tissues were higher than those in OA patients by real-time PCR (6 RA cases vs. 6 OA cases) (p=0.010 and 0.016, respectively). On the other hand, there was no significant difference in the survivin delta-Ex3 expression levels between the RA and OA synovial tissues (p=0.150) (Figure 1). In the IHC analyses, survivin delta-Ex3 was expressed in both RA and OA synovial tissues, while survivin 2B was strongly expressed in RA tissues and hardly expressed in OA tissues. In addition, the serum survivin 2B levels of RA patients were higher than those of OA patients and healthy controls (40 RA cases vs. 16 OA + controls cases) (mean 17.9 µg/ml vs. 6.1 µg/ml, p=0.019). Furthermore, double staining by IHC revealed that survivin and CD55 merged, so survivin was mainly expressed in synovial fibroblasts. Transfection experiments revealed that survivin delta-Ex3-overexpressing fibroblasts were fast-growing and their sensitivity to anti-metabolites was elevated compared with that of fibroblasts transfected with a vector plasmid. On the other hand, survivin 2B-overexpressing fibroblasts were fast-growing, but their sensitivity to anti-metabolites was not elevated compared with that of fibroblasts transfected with a vector plasmid.

Conclusion: The expression of survivin 2B in synovial tissue and serum samples was a specific biomarker of RA. In addition, survivin 2B-expressing fibroblasts were associated with proliferation and resistance to an anti-metabolite. Therefore, survivin 2B is a RA-specific molecule and might contribute to the rheumatoid synovial hyperplasia.

Figure 1. Relative expression levels of survivin splicing variants in synovial tissues from RA and OA

   Results were presented relative to expression of the housekeeping gene Hprt. * Mann-whitney U test, p<0.05


Disclosure:

S. Mokuda,
None;

T. Miyazaki,
None;

J. Masumoto,
None;

M. Kanno,
None;

K. Takasugi,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-expression-of-proto-oncogene-survivin-splicing-variant-2b-in-synovial-tissues-and-blood-from-patients-with-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology